GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » ROC %

Pharmaxis (Pharmaxis) ROC % : -226.15% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Pharmaxis's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was -226.15%.

As of today (2024-05-06), Pharmaxis's WACC % is 10.12%. Pharmaxis's ROC % is -236.13% (calculated using TTM income statement data). Pharmaxis earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Pharmaxis ROC % Historical Data

The historical data trend for Pharmaxis's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis ROC % Chart

Pharmaxis Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -148.73 -126.27 -147.91 -168.39 -200.69

Pharmaxis Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -161.40 -199.33 -209.57 -217.44 -226.15

Pharmaxis ROC % Calculation

Pharmaxis's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=-16.972 * ( 1 - 0% )/( (9.52 + 7.394)/ 2 )
=-16.972/8.457
=-200.69 %

where

Pharmaxis's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-11.388 * ( 1 - 0% )/( (7.394 + 2.677)/ 2 )
=-11.388/5.0355
=-226.15 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaxis  (OTCPK:PXSLY) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Pharmaxis's WACC % is 10.12%. Pharmaxis's ROC % is -236.13% (calculated using TTM income statement data). Pharmaxis earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Pharmaxis ROC % Related Terms

Thank you for viewing the detailed overview of Pharmaxis's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaxis (Pharmaxis) Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines